Julio Cesar Teixeira
Julio Cesar Teixeira
Associate Professor, Department of Obstetrics & Gynecology, University of Campinas (UNICAMP)
E-mail confirmado em unicamp.br - Página inicial
Título
Citado por
Citado por
Ano
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper, EL Franco, C Wheeler, DG Ferris, D Jenkins, A Schuind, ...
The lancet 364 (9447), 1757-1765, 2004
21612004
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a …
J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ...
The Lancet 374 (9686), 301-314, 2009
18072009
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of …
J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ...
The Lancet 369 (9580), 2161-2170, 2007
15002007
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double …
M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ...
The lancet oncology 13 (1), 89-99, 2012
7462012
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis …
CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ...
The lancet oncology 13 (1), 100-110, 2012
5052012
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.
WCM Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR ...
Lancet oncology 16, 775-86, 2015
2512015
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination
PS Naud, CM Roteli-Martins, NS De Carvalho, JC Teixeira, PC de Borba, ...
Human vaccines & immunotherapeutics 10 (8), 2147-2162, 2014
2442014
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up
CM Roteli-Martins, P Naud, P De Borba, JC Teixeira, NS De Carvalho, ...
Human vaccines & immunotherapeutics 8 (3), 390-397, 2012
2222012
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women
N De Carvalho, J Teixeira, CM Roteli-Martins, P Naud, P De Borba, ...
Vaccine 28 (38), 6247-6255, 2010
2112010
Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18
A Szarewski, WAJ Poppe, SR Skinner, CM Wheeler, J Paavonen, P Naud, ...
International Journal of Cancer 131 (1), 106-116, 2012
1392012
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study
U Jaisamrarn, X Castellsague, SM Garland, P Naud, J Palmroth, ...
PloS one 8 (11), e79260, 2013
1372013
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6· 4 years
GlaxoSmithKline Vaccine HPV-007 Study Group
The Lancet 374 (9706), 1975-1985, 2009
1142009
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
ER Bahmanyar, J Paavonen, P Naud, J Salmerón, SN Chow, D Apter, ...
Gynecologic oncology 127 (3), 440-450, 2012
1002012
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation
A Szarewski, SR Skinner, SM Garland, B Romanowski, TF Schwarz, ...
The Journal of infectious diseases 208 (9), 1391-1396, 2013
842013
HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRI-CIA …
J Paavonen
Lancet 374, 301-314, 2009
832009
HPV Vaccine Study group: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a …
DM Harper
Lancet 367 (9518), 1247-1255, 2006
832006
Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc …
SM Garland, J Paavonen, U Jaisamrarn, P Naud, J Salmerón, SN Chow, ...
International journal of cancer 139 (12), 2812-2826, 2016
652016
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women
H Trottier, SM Mahmud, L Lindsay, D Jenkins, W Quint, SL Wieting, ...
Cancer Epidemiology and Prevention Biomarkers 18 (3), 854-862, 2009
652009
Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine
S Gall, J Teixeira, C Wheeler, P Naud, D Harper, E Franco, W Quint, ...
Cancer Research 67 (9 Supplement), 4900-4900, 2007
632007
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control …
X Castellsagué, P Naud, SN Chow, CM Wheeler, MJV Germar, ...
The Journal of infectious diseases 210 (4), 517-534, 2014
562014
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20